Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balstilimab - Agenus/Ludwig Institute for Cancer Research

Drug Profile

Balstilimab - Agenus/Ludwig Institute for Cancer Research

Alternative Names: AGEN-2034; BAL - Agenus/Ludwig Institute for Cancer Research; RebmAb-700

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus; Ludwig Institute for Cancer Research
  • Developer Agenus; Betta Pharmaceuticals Co Ltd; Oxford BioTherapeutics; Rottapharm Biotech
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II/III Solid tumours
  • Phase II Adenocarcinoma; Colorectal cancer; Haemangiosarcoma; Lymphoma; Oropharyngeal cancer; Renal cell carcinoma; Soft tissue sarcoma
  • Phase I/II Triple negative breast cancer
  • Phase I Adenoid cystic carcinoma

Most Recent Events

  • 20 Mar 2024 Immune Oncology Research Institute plans a phase II trial for Non-small cell lung cancer (First line therapy, Metastatic disease, Combination therapy, Late-stage disease) in Armenia (IV), in May 2024 (NCT06322108, IMMONC0008)
  • 08 Mar 2024 Weill Medical College of Cornell University in collaboration with plans a phase II trial for Colorectal cancer (Metastatic disease, Combination therapy) in USA (IV, Infusion) (NCT06300463)
  • 01 Feb 2024 Phase-II clinical trials in Adenocarcinoma (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT06251973)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top